Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

-- Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months on setmelanotide therapy; mean BMI decrease of 21.3% in patients (n=5) who reached six months --